Caps1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Caps1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The CAPS1 gene (also known as CADPS or CAPS) encodes Calcium-Dependent Activator Protein for Secretion 1, a critical regulator of regulated secretion from [neurons](/entities/neurons) and neuroendocrine cells. CAPS1 is essential for the priming and fusion of dense-core vesicles, which contain neuropeptides, hormones, and other signaling molecules. This gene is located on chromosome 3p14.2 and is expressed broadly throughout the nervous system and in various endocrine tissues.
Key points:
Essential for dense-core vesicle priming and fusion
Critical for neuropeptide and BDNF secretion
Implicated in Alzheimer's disease and autism
Regulates insulin secretion in pancreatic beta cells
Gene Structure and Evolution
The CAPS1 gene spans approximately 45 kb of genomic DNA and contains 34 exons encoding a protein of 1,241 amino acids. The gene has conserved orthologs across vertebrates, with high homology to CAPS2 (CADPS2), suggesting functional redundancy in some contexts. Alternative splicing produces multiple transcript variants with tissue-specific expression patterns.
Function
CAPS1 regulates several key cellular processes:
Dense-Core Vesicle Release
Vesicle priming - prepares vesicles for Ca2+-triggered fusion
[Hippocampus](/brain-regions/hippocampus) - CA1 and dentate gyrus
Amygdala - central nucleus
Hypothalamus - paraventricular and supraoptic nuclei
Cerebellum - Purkinje cells
Peripheral Tissues
Pancreas - beta cells
Adrenal medulla - chromaffin cells
Pituitary - anterior and posterior lobes
Molecular Mechanisms
Protein Domains
Interaction Partners
SNARE proteins - syntaxin, SNAP-25
Munc18 - vesicle priming
Synaptotagmin - calcium sensor
RIM - active zone organization
Therapeutic Implications
Drug Development Targets
CAPS1 activators - enhance BDNF secretion
Small molecule modulators - stabilize protein function
Gene therapy - AAV-CAPS1 delivery
Experimental Approaches
AAV vectors - restore CAPS1 function
Cell therapy - neuronal replacement
Peptide analogs - functional domains
Animal Models
Knockout Studies
Caps1 knockout - neonatal lethality
Conditional knockouts - secretion deficits
Brain-specific knockouts - BDNF release defects
Transgenic Models
Human CAPS1 knock-in - disease modeling
Reporter constructs - expression patterns
Background
The study of Caps1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.